Compare ENTA & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | MATV |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.7M | 440.9M |
| IPO Year | 2012 | 1996 |
| Metric | ENTA | MATV |
|---|---|---|
| Price | $13.71 | $7.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | 245.3K | ★ 476.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.24% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | $2.97 |
| Revenue Next Year | N/A | $4.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $6.44 | $6.17 |
| 52 Week High | $17.15 | $15.48 |
| Indicator | ENTA | MATV |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 48.68 |
| Support Level | $13.19 | $7.21 |
| Resistance Level | $13.97 | $8.32 |
| Average True Range (ATR) | 0.80 | 0.39 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 30.12 | 62.18 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.